Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Marker Therapeutics Q3 2026 Results: Net Loss of $1.84M, Loss Narrows

Marker Therapeutics, Inc. reported financial results for the quarter ended September 30, 2026, highlighting continued progress in its clinical-stage cell therapy pipeline. The company maintained a net loss as it invests in R&D, with sufficient cash reserves to support operations into the following year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-1.8-2.0
EPS (diluted, $ a share)$-0.10$-0.12

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MRKR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Marker Therapeutics, Inc.: key numbers

Share price
$0.8286Close, Nov 16
Market cap
$13.8M
Shares outstanding
16.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Marker Therapeutics, Inc.

All →
7:13 AM ET 8-K
Contract Win

Marker Therapeutics Wins $2.6M Contract from Food & Drug Administration

Marker Therapeutics was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to advance its lead MAR-T cell therapy, MT-601, for pancreatic cancer. The non-dilutive funding will support a Phase 1 clinical study in patients with locally advanced unresectable pancreatic cancer. Marker was one of only six recipients selected from 66 applications in fiscal year 2026.

Value
$2.6M
Counterparty
Food & Drug Administration

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.